Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-κB-Mediated FANCL Transcription in Bladder Cancer.

IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Dose-Response Pub Date : 2025-12-18 eCollection Date: 2025-10-01 DOI:10.1177/15593258251411761
Chen Li, Guanglin Lv, Zhuang Xiong, Zhenfan Wang
{"title":"Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-κB-Mediated FANCL Transcription in Bladder Cancer.","authors":"Chen Li, Guanglin Lv, Zhuang Xiong, Zhenfan Wang","doi":"10.1177/15593258251411761","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Cisplatin, a frontline chemotherapeutic agent for bladder cancer (BC), induces DNA interstrand crosslinks that are primarily repaired through the Fanconi anemia (FA) pathway. Hyperactivation of this repair mechanism contributes to cisplatin resistance, underscoring the need for FA-targeted sensitizers. This study investigated the effect of ginsenoside Rh2 on FA signaling and cisplatin sensitivity in bladder cancer cells.</p><p><strong>Methods: </strong>Bladder cancer cell lines (T24, 5637, and RT4) were treated with cisplatin, with or without Rh2 pretreatment. FANCI/FANCD2 (ID2) complex monoubiquitination, FANCD2 foci formation, and interactions with downstream repair proteins (FANCP, FANCQ, PCNA) were examined. FANCL expression was analyzed at the transcriptional level, and rescue experiments were performed by FANCL overexpression. NF-κB signaling involvement was assessed using pharmacological agonists. A T24 xenograft model was used to validate in vivo efficacy.</p><p><strong>Results: </strong>Cisplatin induced ID2 complex monoubiquitination, confirming FA pathway activation. Rh2 pretreatment abolished this modification and reduced FANCD2 foci formation, leading to persistent interstrand crosslinks without affecting intrastrand repair. Rh2 disrupted FANCD2- FANCP/FANCQ/PCNA interactions and selectively suppressed FANCL transcription. Overexpression of FANCL restored ID2 monoubiquitination despite Rh2 exposure. NF-κB agonists reversed Rh2-induced FANCL downregulation and FA inhibition. In vivo, Rh2 combined with cisplatin significantly reduced tumor growth in T24 xenografts, whereas NF-κB stimulation counteracted this effect.</p><p><strong>Conclusion: </strong>Ginsenoside Rh2 suppresses NF-κB signaling to transcriptionally downregulate FANCL, thereby impairing FA pathway-mediated DNA repair and enhancing cisplatin cytotoxicity in bladder cancer. These findings highlight Rh2 as a potential combinatorial agent to overcome platinum resistance.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"23 4","pages":"15593258251411761"},"PeriodicalIF":2.8000,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717414/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dose-Response","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15593258251411761","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Cisplatin, a frontline chemotherapeutic agent for bladder cancer (BC), induces DNA interstrand crosslinks that are primarily repaired through the Fanconi anemia (FA) pathway. Hyperactivation of this repair mechanism contributes to cisplatin resistance, underscoring the need for FA-targeted sensitizers. This study investigated the effect of ginsenoside Rh2 on FA signaling and cisplatin sensitivity in bladder cancer cells.

Methods: Bladder cancer cell lines (T24, 5637, and RT4) were treated with cisplatin, with or without Rh2 pretreatment. FANCI/FANCD2 (ID2) complex monoubiquitination, FANCD2 foci formation, and interactions with downstream repair proteins (FANCP, FANCQ, PCNA) were examined. FANCL expression was analyzed at the transcriptional level, and rescue experiments were performed by FANCL overexpression. NF-κB signaling involvement was assessed using pharmacological agonists. A T24 xenograft model was used to validate in vivo efficacy.

Results: Cisplatin induced ID2 complex monoubiquitination, confirming FA pathway activation. Rh2 pretreatment abolished this modification and reduced FANCD2 foci formation, leading to persistent interstrand crosslinks without affecting intrastrand repair. Rh2 disrupted FANCD2- FANCP/FANCQ/PCNA interactions and selectively suppressed FANCL transcription. Overexpression of FANCL restored ID2 monoubiquitination despite Rh2 exposure. NF-κB agonists reversed Rh2-induced FANCL downregulation and FA inhibition. In vivo, Rh2 combined with cisplatin significantly reduced tumor growth in T24 xenografts, whereas NF-κB stimulation counteracted this effect.

Conclusion: Ginsenoside Rh2 suppresses NF-κB signaling to transcriptionally downregulate FANCL, thereby impairing FA pathway-mediated DNA repair and enhancing cisplatin cytotoxicity in bladder cancer. These findings highlight Rh2 as a potential combinatorial agent to overcome platinum resistance.

人参皂苷Rh2通过抑制NF-κ b介导的FANCL在膀胱癌中的转录抑制Fanconi贫血途径
目的:顺铂是膀胱癌(BC)的一线化疗药物,可诱导DNA链间交联,主要通过Fanconi贫血(FA)途径修复。这种修复机制的过度激活有助于顺铂耐药,强调了对fa靶向增敏剂的需求。本研究探讨了人参皂苷Rh2对膀胱癌细胞FA信号转导及顺铂敏感性的影响。方法:采用顺铂治疗膀胱癌细胞株(T24、5637和RT4),同时进行或不进行Rh2预处理。检测FANCI/FANCD2 (ID2)复合体单泛素化、FANCD2病灶形成以及与下游修复蛋白(FANCP、FANCQ、PCNA)的相互作用。在转录水平分析FANCL的表达,并通过FANCL过表达进行拯救实验。使用药物激动剂评估NF-κB信号的参与情况。采用T24异种移植物模型验证其体内疗效。结果:顺铂诱导ID2复合体单泛素化,证实FA通路激活。Rh2预处理消除了这种修饰,减少了FANCD2焦点的形成,导致持续的链间交联而不影响链内修复。Rh2破坏FANCD2- FANCP/FANCQ/PCNA相互作用,选择性抑制FANCL转录。尽管Rh2暴露,但FANCL的过表达恢复了ID2的单泛素化。NF-κB激动剂可逆转rh2诱导的FANCL下调和FA抑制。在体内,Rh2联合顺铂可显著降低T24异种移植物的肿瘤生长,而NF-κB刺激可抵消这种作用。结论:人参皂苷Rh2通过抑制NF-κB信号通路转录下调FANCL,从而损害FA途径介导的DNA修复,增强顺铂在膀胱癌中的细胞毒性。这些发现强调了Rh2作为克服铂耐药性的潜在组合剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Dose-Response
Dose-Response PHARMACOLOGY & PHARMACY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
4.90
自引率
4.00%
发文量
140
审稿时长
>12 weeks
期刊介绍: Dose-Response is an open access peer-reviewed online journal publishing original findings and commentaries on the occurrence of dose-response relationships across a broad range of disciplines. Particular interest focuses on experimental evidence providing mechanistic understanding of nonlinear dose-response relationships.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书